Vernalis PLC | Cash Flow

Fiscal year is July-June. All values GBP Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
4,001.00
2,940.00
6,401.00
14,495.00
21,562.00
Depreciation, Depletion & Amortization
1,775.00
1,366.00
1,368.00
1,320.00
1,537.00
Other Funds
5,913.00
5,822.00
7,903.00
-
-
Funds from Operations
2,638.00
3,447.00
6,727.00
20,011.00
21,445.00
Changes in Working Capital
1,527.00
386.00
3,256.00
529.00
1,718.00
Net Operating Cash Flow
1,111.00
3,061.00
9,983.00
20,540.00
19,727.00
Capital Expenditures
2,622.00
6,177.00
8,479.00
283.00
5,207.00
Sale of Fixed Assets & Businesses
-
-
-
-
4.00
Purchase/Sale of Investments
-
-
-
27,329.00
24,906.00
Net Investing Cash Flow
2,622.00
6,177.00
8,479.00
31,289.00
19,703.00
Net Financing Cash Flow
5,913.00
5,824.00
7,916.00
39,236.00
2.00
Net Change in Cash
1,276.00
2,655.00
9,489.00
11,811.00
181.00
Free Cash Flow
1,757.00
3,744.00
10,988.00
20,752.00
20,155.00
Deferred Taxes & Investment Tax Credit
-
-
-
-
696.00
Net Assets from Acquisitions
-
-
-
3,677.00
-
Change in Capital Stock
-
2.00
13.00
39,236.00
2.00
Exchange Rate Effect
904.00
759.00
1,057.00
782.00
203.00

About Vernalis

View Profile
Address
100 Berkshire Place
Winnersh Berkshire RG41 5RD
United Kingdom
Employees -
Website http://vernalis.com
Updated 09/14/2018
Vernalis Plc is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U. S.